Renal Perfusion Quantification With 62CU PET

Information

  • Research Project
  • 6943070
  • ApplicationId
    6943070
  • Core Project Number
    R44DK058466
  • Full Project Number
    5R44DK058466-04
  • Serial Number
    58466
  • FOA Number
    PA-01-72
  • Sub Project Id
  • Project Start Date
    7/1/2001 - 23 years ago
  • Project End Date
    8/31/2009 - 15 years ago
  • Program Officer Name
    MOXEY-MIMS, MARVA M.
  • Budget Start Date
    9/1/2005 - 19 years ago
  • Budget End Date
    8/31/2009 - 15 years ago
  • Fiscal Year
    2005
  • Support Year
    4
  • Suffix
  • Award Notice Date
    9/5/2005 - 19 years ago

Renal Perfusion Quantification With 62CU PET

DESCRIPTION (provided by applicant): Serious kidney disease, involving substantial impairment of function, affects approximately 3.5 million Americans. Quantitative measurement of regional and global renal perfusion can provide important diagnostic information in the evaluation of such patients. Despite an intense search within the research community for a suitable non-invasive method for such measurements, existing techniques have severe limitations including lack of quantification (MRI), dependence on highly skilled users (color Doppler) or inappropriateness for use in humans (radiolabeled microspheres). Although global kidney function can be assessed using clearance indicators, these techniques provide no direct perfusion information. With a suitable radioactive agent, PET imaging can provide absolute quantification of regional blood flow with excellent spatial resolution and can be applied conveniently in humans. We propose to employ the PET agent 62Cu-ETS for this unique renal application. This agent has a short 9.7minute physical half-life, permitting safe, repeated use in humans and can be nationally distributed through use of a PTI developed generator. In our Phase I studies, this agent has demonstrated uniquely high renal uptake in humans and also demonstrated linear uptake to very high renal flow levels in a pig model. The proposed Phase II work will involve refinement of the radiochemical process for clinical production of the 62Cu-ETS and the necessary work for submission of an Investigational New Drug Application. In addition we will continue our work in Phase I by validating the application of 62Cu-ETS for PET quantification of regional renal perfusion in a pig model of acute focal renal injury, as well as translating the model to 62Cu-ETS quantification of regional renal perfusion in humans. Given the strength of PET and the characteristics of the Cu-ETS tracer, this imaging procedure can provide an ideal non-invasive technique for absolute quantitative measurement of both regional and global renal blood flow with far-reaching benefits in patient management and diagnosis.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    655474
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:655474\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PROPORTIONAL TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HOUSTON
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    77054
  • Organization District
    UNITED STATES